Bacterial respiratory pathogens in children with inherited immune and airway disorders: Nasopharyngeal carriage and disease risk

Pediatric Infectious Disease Journal

Volumn 32, Issue 4, 2013, Pages 399-404

  Verhagen, Lilly M ^a   Luesink, Maaike ^a   Warris, Adilia ^a   De Groot, Ronald ^a   Hermans, Peter W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Children; Cystic fibrosis; Primary immunodeficiencies; Respiratory tract pathogens; Sickle cell disease

Indexed keywords

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CYSTIC FIBROSIS; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOPATHOLOGY; LONGITUDINAL STUDY; NASOPHARYNGEAL COLONIZATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK; SICKLE CELL ANEMIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

CARRIER STATE; CHILD; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; IMMUNE SYSTEM DISEASES; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PREVALENCE; RESPIRATORY TRACT INFECTIONS; RISK ASSESSMENT; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 84876225633     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31827db77a     Document Type: Article

References (85)

1. Bogaert D, van Belkum A, Sluijter M, et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet. 2004;363:1871-1872.
2. Harrison LM, Morris JA, Telford DR, et al. The nasopharyngeal bacterial flora in infancy: effects of age, gender, season, viral upper respiratory tract infection and sleeping position. FEMS Immunol Med Microbiol. 1999;25:19-28.
3. Leibovitz E, Dragomir C, Sfartz S, et al. Nasopharyngeal carriage of multidrug-resistant Streptococcus pneumoniae in institutionalized HIV-infected and HIV-negative children in northeastern Romania. Int J Infect Dis. 1999;3:211-215.
4. Masuda K, Masuda R, Nishi J, et al. Incidences of nasopharyngeal colonization of respiratory bacterial pathogens in Japanese children attending daycare centers. Pediatr Int. 2002;44:376-380.
5. Sekhar S, Chakraborti A, Kumar R. Haemophilus influenzae colonization and its risk factors in children aged <2 years in northern India. Epidemiol Infect. 2009;137:156-160.
6. De Lencastre H, Kristinsson KG, Brito-Avô A, et al. Carriage of respiratory tract pathogens and molecular epidemiology of Streptococcus pneumoniae colonization in healthy children attending day care centers in Lisbon, Portugal. Microb Drug Resist. 1999;5:19-29.
7. O'Brien KL, Wolfson LJ, Watt JP, et al.; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893-902.
8. Watt JP, Wolfson LJ, O'Brien KL, et al.; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet. 2009;374:903-911.
9. Rosenzweig SD, Holland SM. Recent insights into the pathobiology of innate immune deficiencies. Curr Allergy Asthma Rep. 2011;11:369-377.
10. Stenbit AE, Flume PA. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2011;17:442-447.
11. Ramakrishnan M, Moisi JC, Klugman KP, et al. Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:329-337.
12. Watson K, Carville K, Bowman J, et al.; Kalgoorlie Otitis Media Research Project Team. Upper respiratory tract bacterial carriage in Aboriginal and non-Aboriginal children in a semi-arid area of Western Australia. Pediatr Infect Dis J. 2006;25:782-790.
13. Bogaert D, De Groot R, Hermans PW Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4:144-154.
14. Vu HT, Yoshida LM, Suzuki M, et al. Association between nasopharyngeal load of Streptococcus pneumoniae, viral coinfection, and radiologi-cally confirmed pneumonia in Vietnamese children. Pediatr Infect Dis J. 2011;30:11-18.
15. Syrjänen RK, Auranen KJ, Leino TM, et al. Pneumococcal acute otitis media in relation to pneumococcal nasopharyngeal carriage. Pediatr Infect Dis J. 2005;24:801-806.
16. Tocheva AS, Jefferies JM, Rubery H, et al. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Vaccine. 2011;29:4400-4404.
17. Leach AJ, Morris PS, McCallum GB, et al. Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001. BMC Infect Dis. 2009;9:121.
18. Rodenburg GD, de Greeff SC, Jansen AG, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerging Infect Dis. 2010;16:816-823.
19. st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000;13:302-317.
20. Gessner BD, Adegbola RA. The impact of vaccines on pneumonia: key lessons from Haemophilus influenzae type b conjugate vaccines. Vaccine. 2008;26(suppl 2):B3-B8.
21. Ladhani S, Slack MP, Heath PT, et al.; European Union Invasive Bacterial Infection Surveillance participants. Invasive Haemophilus influenzae Disease, Europe, 1996-2006. Emerging Infect Dis. 2010;16:455-463.
22. Laupland KB, Schonheyder HC, Ostergaard C, et al.; International Bacteremia Surveillance Collaborative. Epidemiology of Haemophilus influenzae bacteremia: a multi-national population-based assessment. J Infect. 2011;62:142-148.
23. Murphy TF, Faden H, Bakaletz LO, et al. Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J. 2009;28:43-48.
24. Faden H, Duffy L, Wasielewski R, et al. Relationship between nasopharyngeal colonization and the development of otitis media in children. Ton-awanda/Williamsville Pediatrics. J Infect Dis. 1997;175:1440-1445.
25. Harabuchi Y, Faden H, Yamanaka N, et al. Nasopharyngeal colonization with nontypeable Haemophilus influenzae and recurrent otitis media. Ton-awanda/Williamsville Pediatrics. J Infect Dis. 1994;170:862-866.
26. Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005;5:751-762.
27. Delaney HM, Wang E, Melish M. Comprehensive strategy including prophylactic mupirocin to reduce Staphylococcus aureus colonization and infection in high-risk neonates [published online ahead of print August 23, 2012]. J Perinatol. doi: 10.1038/jp.2012.102.
28. Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis. 2003;36:281-285.
29. Van Rijen M, Bonten M, Wenzel R, et al. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev. 2008;CD006216.
30. Raz R, Miron D, Colodner R, et al. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med. 1996; 156:1109-1112.
31. Chang SH, Yang YH, Chiang BL. Infectious pathogens in pediatric patients with primary immunodeficiencies. J Microbiol Immunol Infect. 2006;39:503-515.
32. Picard C, von Bernuth H, Ghandil P, et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore). 2010;89:403-425.
33. Cederlund A, Olliver M, Rekha RS, et al. Impaired release of antimicrobial peptides into nasal fluid of hyper-IgE and CVID patients. PLoS ONE. 2011;6:e29316.
34. van Rossum AM, Lysenko ES, Weiser JN. Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneumoniae in a murine model. Infect Immun. 2005;73:7718-7726.
35. Malley R, Trzcinski K, Srivastava A, et al. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA. 2005;102:4848-4853.
36. Lu YJ, Gross J, Bogaert D, et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 2008;4:e1000159.
37. Albiger B, Sandgren A, Katsuragi H, et al. Myeloid differentiation factor 88-dependent signalling controls bacterial growth during colonization and systemic pneumococcal disease in mice. Cell Microbiol. 2005;7:1603-1615.
38. Ladhani S, Heath PT, Slack MPE, et al. Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes. Clin Microbiol Infect. 2010;16:958-954.
39. Micol R, Kayal S, Mahlaoui N, et al. Protective effect of IgM against colonization of the respiratory tract by nontypeable Haemophilus influenzae in patients with hypogammaglobulinemia. J Allergy Clin Immunol. 2012;129:770-777.
40. Zhang Q, Bernatoniene J, Bagrade L, et al. Serum and mucosal antibody responses to pneumococcal protein antigens in children: relationships with carriage status. Eur J Immunol. 2006;36:46-57.
41. Dagan R, Givon-Lavi N, Fraser D, et al. Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis. 2005;192:367-376.
42. Wood P, Stanworth S, Burton J, et al.; UK Primary Immunodeficiency Network. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol. 2007;149:410-423.
43. Samuelson A, Borrelli S, Gustafson R, et al. Characterization of Haemophilus influenzae isolates from the respiratory tract of patients with primary antibody deficiencies: evidence for persistent colonizations. Scand J Infect Dis. 1995;27:303-313.
44. Freeman AF, Holland SM. Antimicrobial prophylaxis for primary immunodeficiencies. Curr Opin Allergy Clin Immunol. 2009;9:525-530.
45. Chovancova Z, Vlkova M, Litzman J, et al. Antibody forming cells and plas-mablasts in peripheral blood in CVID patients after vaccination. Vaccine. 2011;29:4142-450.
46. Perkins SL. Pediatric red cell disorders and pure red cell aplasia. Am J Clin Pathol. 2004;122(suppl):S70-S86.
47. Williams TN, Uyoga S, Macharia A, et al. Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet. 2009;374:1364-1370.
48. Schaumburg F, Biallas B, Feugap EN, et al. Carriage of encapsulated bacteria in Gabonese children with sickle cell anaemia. Clin Microbiol Infect. 2013;19:235-241.
49. Anglin DL, Siegel JD, Pacini DL, et al. Effect of penicillin prophylaxis on nasopharyngeal colonization with Streptococcus pneumoniae in children with sickle cell anemia. J Pediatr. 1984;104:18-22.
50. Daw NC, Wilimas JA, Wang WC, et al. Nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae in children with sickle cell disease. Pediatrics. 1997;99:E7.
51. Chesney PJ, Wilimas JA, Presbury G, et al. Penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae causing sepsis and meningitis in children with sickle cell disease. J Pediatr. 1995;127:526-532.
52. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44:1428-1433.
53. Alexander E, Telfer P, Rashid H, et al. Nasopharyngeal carriage rate of Streptococcus pneumoniae in children with sickle cell disease before and after the introduction of heptavalent pneumococcal conjugate vaccine. J Infect Public Health. 2008;1:40-44.
54. Ahmed SG. The role of infection in the pathogenesis of vaso-ocelusive crisis in patients with sickle cell disease. Mediterr J Hematol Infect Dis. 2011;3:e2011028.
55. Hirst C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev. 2012;9:CD003427.
56. Goldblatt D, Johnson M, Evans J. Antibody responses to Haemophilus influenzae type b conjugate vaccine in sickle cell disease. Arch Dis Child. 1996;75:159-161.
57. Davies EG, Riddington C, Lottenberg R, et al. Pneumococcal vaccines for sickle cell disease. Cochrane Database Syst Rev. 2004;CD003885.
58. Spoulou VI, Tsoumas DL, Ladis V, et al. Natural and vaccine-induced immunity against Haemophilus influenzae type b in patients with beta-thalassemia. Vaccine. 2006;24:3050-3053.
59. Cimaz R, Mensi C, D'Angelo E, et al. Safety and immunogenicity of a conjugate vaccine against Haemophilus influenzae type b in splenecto-mized and nonsplenectomized patients with Cooley anemia. J Infect Dis. 2001;183:1819-1821.
60. Stoehr GA, Rose MA, Eber SW, et al. Immunogenic ity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis. Br J Haematol. 2006;132:788-790.
61. Yanni E, Grosse SD, Yang Q, et al. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. J Pediatr. 2009;154:541-545.
62. Advisory Committee on Immunization Practices (ACIP). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children. MMWR. 2010;59:258-61.
63. Howard-Jones M, Randall L, Bailey-Squire B, et al. An audit of immunisation status of sickle cell patients in Coventry, UK. J Clin Pathol. 2009;62:42-45.
64. Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001;32:356-366.
65. del Campo R, Morosini MI, de la Pedrosa EG, et al.; Spanish Pneumococcal Infection Study Network. Population structure, antimicrobial resistance, and mutation frequencies of Streptococcus pneumoniae isolates from cystic fibrosis patients. J Clin Microbiol. 2005;43:2207-2214.
66. Sly PD, Brennan S, Gangell C, et al.; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am JRespir Crit Care Med. 2009;180:146-152.
67. Chidekel AS, Steele-Moore L, Padman R, et al. Nasopharyngeal colonization in children with Cystic Fibrosis: antibiotic resistance and intrafamilial spread. Infect Dis Clin Prac. 2000;9:333-336.
68. Stone A, Quittell L, Zhou J, et al. Staphylococcus aureus nasal colonization among pediatric cystic fibrosis patients and their household contacts. Pediatr Infect Dis J. 2009;28:895-899.
69. Ridder-Schaphorn S, Ratjen F, Dúbbers A, et al. Nasal Staphylococcus aureus carriage is not a risk factor for lower-airway infection in young cystic fibrosis patients. J Clin Microbiol. 2007;45:2979-2984.
70. Mainz JG, Naehrlich L, Schien M, et al. Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis. Thorax. 2009;64:535-540.
71. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995;151:1075-1082.
72. Balough K, McCubbin M, Weinberger M, et al. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol. 1995;20:63-70.
73. Ranganathan SC, Parsons F, Gangell C, et al.; Australian Respiratory Early Surveillance Team for Cystic Fibrosis. Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis. Thorax. 2011;66:408-413.
74. Kohri K, Ueki IF, Nadel JA. Neutrophil elastase induces mucin production by ligand-dependent epidermal growth factor receptor activation. Am J Physiol Lung Cell Mol Physiol. 2002;283:L531-L540.
75. Reeves EP, Bergin DA, Murray MA, et al. The involvement of glycosami-noglycans in airway disease associated with cystic fibrosis. Scientific World-Journal. 2011;11:959-971.
76. Smyth A. Prophylactic antibiotics in cystic fibrosis: a conviction without evidence? Pediatr Pulmonol. 2005;40:471-476.
77. Cai Y, Chai D, Wang R, et al. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother. 2011;66:968-978.
78. Stutman HR, Lieberman JM, Nussbaum E, et al. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr. 2002;140:299-305.
79. Dasenbrook EC. Update on methicillin-resistant Staphylococcus aureus in cystic fibrosis. Curr Opin Pulm Med. 2011;17:437-441.
80. Gibson RL, Burns JL, Ramsey BW Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168:918-951.
81. Burgess L, Southern KW Pneumococcal vaccines for cystic fibrosis. Cochrane Database Syst Rev. 2012;9:CD008865.
82. Sakhalkar VS, Sarnaik SA, Asmar BI, et al. Prevalence of penicillin-non-susceptible Streptococcus pneumoniae in nasopharyngeal cultures from patients with sickle cell disease. South Med J. 2001;94:401-404.
83. Steele RW, Warrier R, Unkel PJ, et al. Colonization with antibiotic-resistant Streptococcus pneumoniae in children with sickle cell disease. J Pediatr. 1996;128:531-535.
84. Overturf GD, Field R, Lam C, et al. Nasopharyngeal carriage of pneumo-cocci in children with sickle cell disease. Infect Immun. 1980;28:1048-1050.
85. Kateete DP, Kajumbula H, Kaddu-Mulindwa DH, et al. Nasopharyngeal carriage rate of Streptococcus pneumoniae in Ugandan children with sickle cell disease. BMC Res Notes. 2012:5:28.